华大智造股价涨5.13%，财通证券资管旗下1只基金重仓，持有4.5万股浮盈赚取14.04万元

Group 1 - The core viewpoint of the news is that BGI Genomics has seen a stock price increase of 5.13%, reaching 63.88 CNY per share, with a total market capitalization of 26.607 billion CNY [1] - BGI Genomics, established on April 13, 2016, and listed on September 9, 2022, focuses on the life sciences and biotechnology sectors, with 90.89% of its revenue coming from the sales of instruments, reagents, and consumables [1] - The company has a revenue composition of 90.89% from sales of instruments and consumables, 7.10% from services, and 2.01% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Caitong Securities Asset Management has a significant position in BGI Genomics, with 45,000 shares held, accounting for 8.62% of the fund's net value [2] - Caitong Asset Management's Innovation Pharmaceutical Mixed A fund has achieved a year-to-date return of 42.96%, ranking 1719 out of 8155 in its category [2] - The fund manager, Wang Xinyuan, has been in position for 57 days, with the fund's total asset size at 359 million CNY [3]